# OnCo record sotorasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sotorasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sotorasib" ;
  schema:name "Sotorasib"@en ;
  schema:description "Sotorasib (Lumakras) was the first drug to hit KRAS, approved in 2021 after four decades of failure."@en ;
  schema:url <https://onco.cc/drugs/sotorasib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sotorasib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q75175937> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sotorasib>, <https://doi.org/10.1056/NEJMoa2208470>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LUMAKRAS%22>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications>, <https://www.nice.org.uk/guidance/ta781> ;
  onco:status "approved" ;
  onco:modality "Small-molecule inhibitor (KRAS G12C)" ;
  schema:alternateName "Lumakras" ;
  onco:approval "US 2021: KRAS G12C NSCLC, previously treated (accelerated)", "US 2025: KRAS G12C colorectal cancer with panitumumab", "EU 2022: EU brand Lumykras", "US 2025: KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with panitumumab", "England (NICE) 2022: KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer that has progressed on, or after intolerance of, platinum-based chemotherapy or PD-1/PD-L1 immunotherapy" ;
  onco:acceleratedApproval "US 2021-05-28: Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy." ;
  onco:related <https://onco.cc/biomarkers/kras-g12c/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/kras-g12c-colorectal/>, <https://onco.cc/cancers/kras-g12c-nsclc/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/> ;
  onco:trials <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/nct05920356/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct07563738/>, <https://onco.cc/trials/nct05074810/>, <https://onco.cc/trials/nct07172919/>, <https://onco.cc/trials/codebreak-100/>, <https://onco.cc/trials/codebreak-200/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/>, <https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/>, <https://onco.cc/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/> .